Safety Profile and Long-term Tolerability of Vorasidenib

The updated safety analysis demonstrates that liver function test abnormalities predominantly occur during the first year of treatment, with minimal additional cases emerging during extended follow-up. This temporal pattern provides reassurance about long-term hepatic safety with appropriate monitoring.

Five deaths occurred in the treatment arm, including one oligodendroglioma patient who developed metastatic renal cell cancer without tumor progression on vorasidenib. Four astrocytoma patients died, with varying clinical patterns providing insights into treatment resistance mechanisms.

Two patients experienced rapid progression within 5 months of treatment initiation, developing CDKN2A/B deletions indicating transformation to grade 4 disease. These patients survived approximately 5 years from initial diagnosis despite aggressive tumor evolution, suggesting the more aggressive molecular subtype rather than treatment failure.

Two additional astrocytoma patients progressed after approximately 11 months of treatment. One harbored a PI3K-R1 mutation, potentially representing an emerging grade 3 marker associated with treatment resistance. The molecular characteristics of resistance mechanisms continue to evolve as more data becomes available.

Dr. Cloughesy notes these events represent expected outcomes when studying 160 patients with aggressive disease, and his personal experience treating 40 to 50 patients hasn't shown similar patterns, suggesting these may be outlier cases inherent to large clinical trials.

The FDA approved vorasidenib in August 2024 for IDH-mutant gliomas, with regulatory approvals following in multiple countries. The approval encompasses a broad population from gross total resection to biopsy-only patients, providing flexibility for treating physicians to determine optimal treatment timing.